Clozapine therapy for older veterans

Psychiatric Services

Volumn 49, Issue 3, 1998, Pages 340-344

  Sajatovic, Martha ^a   Ramirez, Luis F ^a   Garver, David ^c,d   Thompson, Paul ^b   Ripper, Gary ^c   Lehmann, Laurent S ^e,f  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e Veterans Administration Central Office   (United States)

^f GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ADULT; AGED; ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PSYCHOSIS; SOLDIER; TREATMENT FAILURE; TREATMENT INDICATION;

EID: 0031932626     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.49.3.340     Document Type: Article

References (46)

1. Gurland BJ, Cross PS: Epidemiology of psychopathology in old age: some implications for clinical services. Psychiatric Clinics of North America 5:11-26, 1982
2. Tariot PN, Podgorski CA, Blazina L, et al: Mental disorders in the nursing home: another perspective. American Journal of Psychiatry 150:1063-1069, 1993
3. Malmgren R: Epidemiology of aging, in Textbook of Geriatric Neuropsychiatry. Edited by Coffey CE, Cummings JL. Washington, DC, American Psychiatric Press, 1994
4. Special Committee for Seriously Mentally Ill Veterans: First Animal Report to the Undersecretary for Health. Washington, DC, Department of Veterans Affairs, 1995
5. Sajatovic M, Popli A, Semple W: Health resource utilization over a ten-year period by geriatric veterans with schizophrenia and bipolar disorder. Psychiatric Services 47: 961-965, 1996
6. Jeste DV, Lacro JP, Gilbert DL, et al: Treatment of late-life schizophrenia with neuroleptics. Schizophrenia Bulletin 19:817-827, 1993
7. Smith JM, Baldessarini RJ: Changes in prevalence, severity, and recovery in tardive dyskinesia with old age. Archives of General Psychiatry 37:1368-1373, 1980
8. Kane JM, Woerner M, Lieberman J: Tardive dyskinesia: prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology 8:525-565, 1988
9. Hoffman WF, Ballard C, Turner EH, et al: Three-year follow-up of older schizophrenics: extrapyramidal syndromes, psychiatric symptoms, and ventricular brain ratio. Biological Psychiatry 30:913-926, 1991
10. Ciompi L: Aging and schizophrenic psychosis. Acta Psychiatrica Scandinavica 71(suppl 319):93-105, 1985
11. Davidson M, Harvey PD, Powchick P, et al: Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. American Journal of Psychiatry 152:197-207, 1995
12. Crow TJ: Molecular pathology of schizophrenia: more than one disease process? British Medical Journal 280:66-68, 1980
13. Tran-Johnson TK, Krull AJ, Jeste DV: Late-life schizophrenia and its treatment: pharmacologic issues in older schizophrenic patients. Clinics in Geriatric Medicine 8:401-410, 1992
14. Baldessarini RJ, Frankenburg FR: Clozapine: a novel antipsychotic agent. New England Journal of Medicine 324:746-753, 1991
15. Scholz E, Dichgans J: Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. European Archives of Psychiatry and Neurological Science 235:60-64, 1985
16. Friedman JH, Max J, Swift R: Idiopathic Parkinsons disease in a chronic schizophrenic patient: long-term treatment with clozapine and L-dopa. Clinical Neuropharmacology 10:470-475, 1987
17. Pakkenberg H, Pakkenberg B: Clozapine in the treatment of tremor. Acta Neurologica Scandinavica 73:295-297, 1986
18. Ostergaard K, Dupont E: Clozapine treatment of drug-induced psychotic symptoms in late stages of Parkinson's disease. Acta Neurologica Scandinavica 78:349-350, 1988
19. Factor S, Brown D: Clozapine prevents recurrence of psychosis in Parkinson's disease. Movement Disorders 7:125-131, 1992
20. Wolters EC, Hurwitz TA, Mak E, et al: Clozapine in the treatment of parkinsonian patients with dopaminergic psychosis. Neurology 40:832-834, 1990
21. Oberholzer AF, Hendricksen C, Monsch AV, et al: Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. International Psychogeriatrics 4:187-195, 1992
22. Frankenburg FR, Kalunian D: Clozapine in the elderly. Journal of Geriatric Psychiatry and Neurology 7:129-132, 1994
23. Chengappa KN, Baker RW, Kreinbrook SB, et al: Clozapine use in female geriatric patients with psychosis. Journal of Geriatric Psychiatry and Neurology 8:12-15, 1995
24. Pitner JK, Mintzer JE, Pennypacker LC, et al: Efficacy and adverse effects of clozapine in four elderly psychotic patients. Journal of Clinical Psychiatry 56:180-185, 1995
25. Salzman C, Vaccaro B, Lieff J, et al: Clozapine in older patients with psychosis and behavioral disruption. American Journal of Geriatric Psychiatry 3:26-33, 1995
26. Sajatovic M, Jaskiw G, Konicki PE, et al: Outcome of clozapine therapy for elderly patients with refractory primary psychosis. International Journal of Geriatric Psychiatry 12:553-558, 1997
27. Salzman C: Clozapine in elderly psychotic patients (ltr). Journal of Clinical Psychiatry 57:309, 1996
28. Overall JE, Gorham D: The Brief Psychiatric Rating Scale. Psychological Reports 10:799-812, 1962
29. Guy W: ECDEU Assessment Manual for Psychopathology. Pub (ADM) 76-338. Rockville, Md, National Institute of Mental Health, 1976
30. Moeller FG, Chen Y, Steinberg JL, et al: Risk factors for clozapine discontinuation among 805 patients in the VA hospital system. Annals of Clinical Psychiatry 7:167-173, 1995
31. Meltzer HY, Cola P Way L, et al: Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. American Journal of Psychiatry 150:1630-1638, 1993
32. Revicki DA, Luce BR, Weschler JM, et al: Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hospital and Community Psychiatry 41: 850-854, 1990
33. Lindstrom LH: The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatrica Scandinavica 77:524-529, 1988
34. Idanpaan-Heikkla J, Alhava E, Olkinuora M, et al: Agranulocytosis during treatment with clozapine. European Journal of Clinircal Pharmacology 11:193-198, 1977
35. Griffith RW, Saameli K: Clozapine and agranulocytosis (ltr). Lancet 2:657, 1975
36. Amsler HA, Teerenhovi L, Barth E, et al: Agranulocytosis in patients treated with cloxapine: a study of the Finnish epidemic. Acta Psychiatrica Scandinavica 56:241-248, 1977
37. Anderman B, Griffith RW: Clozapine-induced agranulocytosis: a situation report up to August 1976. European Journal of Clinical Pharmacology 11:199-201, 1977
38. De la Chapelle A, Kari C, Nurminen M, et al: Clozapine-induced agranulocytosis: a genetic and epidemiologic study. Human Genetics 37:183-194, 1977
39. Alvir JM, Lieberman JA, Safferman AZ, et al: Clozapine-induced risk factors in the United States. New England Journal of Medicine 329:152-156, 1993
40. Alvir JM, Lieberman JA: Agranulocytosis: incidence and risk factors. Journal of Clinical Psychiatry 55(suppl 9B):137-138, 1994
41. Small JG, Milstein V, Marhenke JD, et al: Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. Journal of Clinical Psychiatry 48:263-267, 1987
42. Meltzer HY, Burnett S, Bastani B, et al: Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry 41:892-897, 1990
43. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. Journal of Clinical Psychiatry 55:(suppl 9B):102-106, 1994
44. Gerlach J, Peacock L: Motor and mental side effects of clozapine. Journal of Clinical Psychiatry 55(suppl 9B):107-109, 1994
45. Volavka J, Zito J, Vitrai J, et al: Clozapine effects on hostility and aggression in schizophrenia (ltr). Journal of Clinical Psychopharmacology 13:287-289, 1993
46. Meltzer HY, Okayli G: Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact of risk-benefit assessment. American Journal of Psychiatry 152:183-190, 1995